18 and older, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Serum Levels of Ceftazidime and Avibactam Among Critically-ill PatientsPrimary· 8 hours
PK samples obtained around standard of care dosing regimens immediately before and at 1, 2, 4, 6, and 8 hours after administration
Ceftazidime Cmax
Group
Value
95% CI
Subjects Included
80.6
61.2 – 104.1
Avibactam Cmax
Group
Value
95% CI
Subjects Included
15.9
11.8 – 23.0
Sponsor's own description
Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07004049 — Optimising TREATment for Severe Gram-Negative Bacterial Infections
· Phase 4
· recruiting
NCT06818565 — Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients
· NA
· not yet recruiting
NCT06633718 — Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
· Phase 3
· not yet recruiting
NCT05258851 — Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
· Phase 3
· terminated
NCT05413343 — Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
· active not recruiting
Other recruiting trials for Bacterial Infections
Currently open trials in the same condition.
NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant
· Phase 3
· recruiting
NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I
· Phase 1
· recruiting
NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
· Phase 1
· recruiting
NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
· recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
· Phase 2, PHASE3
· active not recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE
· NA
· not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation
· not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia
· NA
· not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus
· NA
· not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 29 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04358991.